MedPath

NMES and Chronic Ankle Instability

Phase 1
Conditions
Chronic Ankle Instability
Interventions
Device: Neuromuscular Electrical Stimulation
Device: Transcutaneous Electrical Nerve Stimulation
Registration Number
NCT04322409
Lead Sponsor
Appalachian State University
Brief Summary

Chronic ankle instability is associated with changes in the nervous system that amount to increased difficulty in activating the stabilizing muscles of the ankle. Neuromuscular Electrical Stimulation involves using electricity to activate those muscles in bursts, and is commonly used to improve muscle function in those with ACL injury. This study will provide 5 treatments over 2 weeks in patients with Chronic Ankle Instability and determine if Electrical Stimulation can change neural excitability, balance, neuromuscular control, and perceived function in these individuals.

Detailed Description

Individuals with joint injuries, including ankle sprain and anterior cruciate ligament (ACL) injury have been observed to exhibit changes in central nervous system function that potentially predispose them for further injury (Needle et al. 2017). In ankle sprains, repeated sensations of rolling and giving-way known as chronic ankle instability (CAI) emerges in nearly 50 percent of those with a history of ankle sprain (Holland et al. 2019), with symptoms tied to changes in central nervous system function. As the understanding of these pathologies have expanded, researchers have begun to attempt to identify neuromodulatory interventions capable of addressing injury-induced maladaptive neuroplasticity, thus improving function (Bruce et al. 2020, In Press).

Among those with ACL injury, one of the most common interventions implemented to overcome muscle activation deficits includes neuromuscular electrical stimulation (NMES) (Lepley et al. 2015). This intervention is often used in the initial stages of post-surgical recovery to improve quadriceps function; however, it's use in other populations of joint injury (i.e. ankle sprain) is far more limited. Some previous research has looked at the effects of NMES on acute ankle sprains, as this is the timeframe in which muscle activation deficits would be most evident (Wainwright et al. 2019), but there is very limited evidence in those with CAI. It was potentially thought that activation deficits are less evident and strengthening may overcome these deficits in those with chronic injury; however, new insights have identified additional mechanisms by which NMES may be effective (Lepley et al. 2015). Aside from generating activation of a generally inactive muscle, NMES when performed at high intensities has been described to improve neuromuscular function through disinhibitory mechanisms. That is that increased somatosensation from the electrical stimulation raises the central nervous sytem's awareness of that muscle's activation, yielding decreased inhibition and ultimately increased neural excitability.

Our previous research using cortically-directed interventions demonstrated that improving neural excitability yielded better function in patients with chronic ankle instability (Bruce et al. 2020). This study will follow a similar framework; however, determining if these changes can be induced via a peripheral intervention. These findings have the ability to reframe the current treatment for CAI.

We are pursuing the following 2 specific aims:

1. To determine if NMES changes neural excitability (MEP size, H:M ratio, silent period) compared to a placebo treatment in participants with chronic ankle instability.

H1: NMES will increase MEP size, H:M ratio, and decrease cortical silent period in individuals with CAI compared to the placebo treatment.

2. To determine if changes in neural excitability related to NMES or placebo treatment result in improved function (balance, muscle activation, outcomes) in participants with chronic ankle instability.

H2: Increased neural excitability will yield improved balance (postural stability indices), muscle activation, and patient-reported function.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
26
Inclusion Criteria

Subjects will be healthy subjects between the ages of 18-35. The primary inclusion criteria for this study is the presence of chronic ankle instability (CAI). According to guidelines from the International Ankle Consortium, this means subjects will report having a history of one or more ankle sprains (the first >1 year ago), and repeated sensations of giving-way as measured by a score >10 on the Identification of Functional Ankle Instability instrument (IDFAI).

Exclusion Criteria
  • History of fracture or surgery to the legs
  • Injury to the lower legs within 3 months prior to reporting for testing that resulted in modified physical activity.
  • Currently involved in an ankle rehabilitation program.
  • Failing to meet standards for the safe practice of transcranial magnetic stimulation and transcranial direct current stimulation (See questionnaire). Briefly, this includes personal or family history of seizure or epilepsy; current medication use that raises risk of seizure; implanted metal, medication devices, etc.; history of brain or heart surgery; and sensitivity of the scalp or skin.

Study & Design

Study Type
INTERVENTIONAL
Study Design
FACTORIAL
Arm && Interventions
GroupInterventionDescription
NMESNeuromuscular Electrical StimulationThe experimental treatment of Neuromuscular Electrical Stimulation over the Peroneus Longus.
TENSTranscutaneous Electrical Nerve StimulationThe placebo treatment of Transcutaneous Electrical Nerve Stimulation over the same region as the peroneus longus
Primary Outcome Measures
NameTimeMethod
Tibialis Anterior corticospinal excitabilityBaseline, Week-2 (end of intervention), Week-4 (retention)

Motor evoked potential size of tibialis anterior

Soleus corticospinal excitabilityBaseline, Week-2 (end of intervention), Week-4 (retention)

Motor evoked potential size of soleus

Peroneus Longus corticospinal excitabilityBaseline, Week-2 (end of intervention), Week-4 (retention)

Motor evoked potential size of peroneus longus

Tibialis anterior reflexive excitabilityBaseline, Week-2 (end of intervention), Week-4 (retention)

H:M ratio of tibialis anterior

Soleus reflexive excitabilityBaseline, Week-2 (end of intervention), Week-4 (retention)

H:M ratio of soleus

Peroneus longus reflexive excitabilityBaseline, Week-2 (end of intervention), Week-4 (retention)

H:M ratio of peroneus longus

Secondary Outcome Measures
NameTimeMethod
Dynamic postural stability indexBaseline, Week-2 (end of intervention), Week-4 (retention)

Postural stability indices during a hop-to-stabilization task

Soleus muscle activationBaseline, Week-2 (end of intervention), Week-4 (retention)

Mean electromyography from the soleus during a hop-to-stabilization task

Peroneus Longus muscle activationBaseline, Week-2 (end of intervention), Week-4 (retention)

Mean electromyography from the peroneus during a hop-to-stabilization task

Ankle Eversion StrengthBaseline, Week-2 (end of intervention), Week-4 (retention)

Isometric ankle eversion strength

Side-to-side Hop TestBaseline, Week-2 (end of intervention), Week-4 (retention)

Time to complete 10 hops over 30 cm lines

Patient-reported outcomesBaseline, Week-2 (end of intervention), Week-4 (retention)

Foot \& Ankle ability measure, Disablement in the Physically Active Scale, Tampa Scale for Kinesiophobia

Foot & Ankle ability measureBaseline, Week-2 (end of intervention), Week-4 (retention)

Subjects complete FAAM questionnaire

Disablement in the Physically Active ScaleBaseline, Week-2 (end of intervention), Week-4 (retention)

Subjects complete DPA questionnaire

Tampa Scale for KinesiophobiaBaseline, Week-2 (end of intervention), Week-4 (retention)

Subjects complete TSK-11 questionnaire

Tibialis Anterior muscle activationBaseline, Week-2 (end of intervention), Week-4 (retention)

Mean electromyography from the tibialis anterior during a hop-to-stabilization task

Trial Locations

Locations (1)

Leon Levine Hall for Health Sciences

🇺🇸

Boone, North Carolina, United States

© Copyright 2025. All Rights Reserved by MedPath